Claims
- 1. A method of treating hyperresorptive bone disorders in humans through the direct inhibition of the Src protein tyrosine kinase comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula I:
- 2. A method of treating hyperresorptive bone disorders in humans through the direct inhibition of the Src protein tyrosine kinase comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula II:
- 3. A method of treating hyperresorptive bone disorders in humans through the direct inhibition of the Src protein tyrosine kinase comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula III:
- 4. A method of treating hyperresorptive bone disorders in humans through the direct inhibition of the Src protein tyrosine kinase comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula IV:
- 5. A method of treating hyperresorptive bone disorders in humans through the direct inhibition of the Src protein tyrosine kinase comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula V:
- 6. A method of treating hyperresorptive bone disorders in humans through the direct inhibition of the Src protein tyrosine kinase comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula VI:
- 7. A method of treating hyperresorptive bone disorders in humans through the direct inhibition of the Src protein tyrosine kinase comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula VII:
- 8. A method of treating hyperresorptive bone disorders in humans through the direct inhibition of the Src protein tyrosine kinase comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula VIII:
- 9. A method of treating hyperresorptive bone disorders in humans through the direct inhibition of the Src protein tyrosine kinase comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula IX:
- 10. A method of treating hyperresorptive bone disorders in humans through the direct inhibition of the Src protein tyrosine kinase comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula X:
- 11. A method of directly inhibiting activity of the Src protein tyrosine kinase in humans for therapeutic purposes comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula I:
- 12. A method of directly inhibiting activity of the Src protein tyrosine kinase in humans for therapeutic purposes comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula II:
- 13. A method of directly inhibiting activity of the Src protein tyrosine kinase in humans for therapeutic purposes comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula III:
- 14. A method of directly inhibiting activity of the Src protein tyrosine kinase in humans for therapeutic purposes comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula IV:
- 15. A method of directly inhibiting activity of the Src protein tyrosine kinase in humans for therapeutic purposes comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula V:
- 16. A method of directly inhibiting activity of the Src protein tyrosine kinase in humans for therapeutic purposes comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula VI:
- 17. A method of directly inhibiting activity of the Src protein tyrosine kinase in humans for therapeutic purposes comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula VII:
- 18. A method of directly inhibiting activity of the Src protein tyrosine kinase in humans for therapeutic purposes comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula VIII:
- 19. A method of directly inhibiting activity of the Src protein tyrosine kinase in humans for therapeutic purposes comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula IX:
- 20. A method of directly inhibiting activity of the Src protein tyrosine kinase in humans for therapeutic purposes comprising administering a pharmaceutically effective amount of a compound including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound having the general formula X:
PRIORITY INFORMATION
[0001] This application claims priority to U.S. provisional application No. 60/303,851, filed Jul. 9, 2001, the entire contents of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60303851 |
Jul 2001 |
US |